Tran Janco Jo Marie, Lamichhane Purushottam, Karyampudi Lavakumar, Knutson Keith L
Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55906;
Department of Immunology, Mayo Clinic, Rochester, MN 55906; and Cancer Vaccines and Immune Therapies Program, Vaccine and Gene Therapy Institute, Port St. Lucie, FL 34987.
J Immunol. 2015 Apr 1;194(7):2985-91. doi: 10.4049/jimmunol.1403134.
Dendritic cells (DCs) play a pivotal role in the tumor microenvironment, which is known to affect disease progression in many human malignancies. Infiltration by mature, active DCs into the tumors confers an increase in immune activation and recruitment of disease-fighting immune effector cells and pathways. DCs are the preferential target of infiltrating T cells. However, tumor cells have means of suppressing DC function or of altering the tumor microenvironment in such a way that immune-suppressive DCs are recruited. Advances in understanding these changes have led to promising developments in cancer-therapeutic strategies targeting tumor-infiltrating DCs to subdue their immunosuppressive functions and enhance their immune-stimulatory capacity.
树突状细胞（DCs）在肿瘤微环境中起着关键作用，众所周知，肿瘤微环境会影响许多人类恶性肿瘤的疾病进展。成熟、活跃的DCs浸润到肿瘤中会增加免疫激活以及抗病免疫效应细胞和通路的募集。DCs是浸润性T细胞的优先靶点。然而，肿瘤细胞有抑制DC功能或改变肿瘤微环境的方法，从而募集免疫抑制性DCs。对这些变化的理解进展已带来了针对肿瘤浸润性DCs的癌症治疗策略的有前景的发展，以抑制其免疫抑制功能并增强其免疫刺激能力。
